Virus News and Research

Latest Virus News and Research

Pitt CVR and Sanofi Pasteur join forces to help assess effectiveness of dengue vaccine

The University of Pittsburgh Center for Vaccine Research (CVR) and Sanofi Pasteur, the vaccines division of Sanofi, have entered a scientific collaboration to help assess the effectiveness of a dengue vaccine once introduced for immunization programs.

16 Apr 2014

Irvine Scientific announces launch of BalanCD MDCK cell culture medium

Irvine Scientific is pleased to announce the launch of its BalanCD MDCK cell culture medium, a next generation cell culture product responding to today's requirements for media used in cell-based vaccine manufacturing. This new flagship product expands Irvine Scientific's current BalanCD product portfolio of animal component-free and chemically-defined media with the addition of a new purpose-built product.

15 Apr 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

15 Apr 2014

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Data from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' lifecycle.

15 Apr 2014

New drug combination proves effective in treating patients with HCV genotype 1

Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials led by Beth Israel Deaconess Medical Center show promise for a new option that could help lead to both an increase in patients cured with a much more simple and tolerable all oral therapy.

15 Apr 2014

High cost of potent hepatitis drug presents challenges across the U.S.

Sovaldi, the hepatitis C treatment drug, is considered a breakthrough for patients with the disease. However, since, it won federal approval in December, lawmakers, insurers and patient advocates have begun an all-out revolt over it's high price point of $1,000 a daily pill or $84,000 over 12 weeks of treatment.

15 Apr 2014

Genetic evidence confirms role of group of virus-fighting genes in cancer development

Researchers have found a major piece of genetic evidence that confirms the role of a group of virus-fighting genes in cancer development.

15 Apr 2014

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Twelve weeks of an investigational oral therapy cured hepatitis C infection in more than 90 percent of patients with liver cirrhosis and was well tolerated by these patients, according to an international study that included researchers from UT Medicine San Antonio and the Texas Liver Institute.

15 Apr 2014

New paper calls for increase in geographically targeted prevention, treatment for HIV-infected people

In U.S. cities, it's not just what you do, but also your address that can determine whether you will get HIV and whether you will survive. A new paper in the American Journal of Public Health illustrates the effects of that geographic disparity - which tracks closely with race and poverty - and calls for an increase in geographically targeted prevention and treatment efforts.

11 Apr 2014

Findings pave way for potential therapy to combat H1N1 flu virus

Flu epidemics cause up to half a million deaths worldwide each year, and emerging strains continually threaten to spread to humans and cause even deadlier pandemics. A study by McGill University professor Maziar Divangahi published by Cell Press on April 10 in the journal Immunity reveals that a drug that inhibits a molecule called prostaglandin E2 (PGE2) increases survival rates in mice infected with a lethal dose of the H1N1 flu virus.

11 Apr 2014

New research provides new hope for liver transplant patients with recurring hepatitis C

New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV).

11 Apr 2014

Scientists discover protein potentially good target for influenza A virus

Scientists at The University of Texas at Austin have discovered that a protein produced by the influenza A virus helps it outwit one of our body's natural defense mechanisms. That makes the protein a potentially good target for antiviral drugs directed against the influenza A virus.

11 Apr 2014

Too much of c-FLIPR protein can trigger autoimmune diseases

So-called c-FLIP proteins inhibit signaling cascades that can lead to apoptosis. This is important temporarily in the response to pathogens to ensure that lymphocytes, a type of immune cells, can proliferate sufficiently.

11 Apr 2014

EU-funded project aims to find solution to combat hepatitis C epidemic in Egypt

New ways to differentiate between chronic and self-clearing infections may help towards effective patient management and reduce drug costs. But there are major challenges in implementation.

11 Apr 2014

Viral hepatitis linked to more deaths than HIV across EU countries

Mortality from viral hepatitis is significantly higher than from HIV/AIDS across EU countries, according to results from The Global Burden of Disease Study 2010 (GBD 2010) which was announced for the first time today at the International Liver CongressTM 2014.

11 Apr 2014

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza.

11 Apr 2014

Assembly Pharmaceuticals, BioCrossroads develop novel drugs that have potential to treat chronic HBV infection

Assembly Pharmaceuticals and BioCrossroads today announced that the BioCrossroads Indiana Seed Fund II has made an investment in Assembly Pharmaceuticals. Assembly is developing novel drugs for the treatment and potential cure of chronic hepatitis B virus (HBV) infection.

10 Apr 2014

Researchers discover how of EBV virus takes over human cells gene regulating machinery

University of Montreal researchers have discovered how a component of the Epstein Barr (EBV) virus takes over our cells gene regulating machinery, allowing the virus to replicate itself.

10 Apr 2014

Johns Hopkins student receives 2014 Excellence in Public Health Award

Ramy El-Diwany, a fifth-year M.D./Ph.D. student at the Johns Hopkins University School of Medicine, has won a 2014 Excellence in Public Health Award from the U.S. Public Health Service (USPHS) Physician Professional Advisory Committee for his contributions to community health services.

10 Apr 2014

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF) for the treatment of chronic hepatitis C virus (HCV) infection.

10 Apr 2014

Virus News and Research

Latest Virus News and Research

Pitt CVR and Sanofi Pasteur join forces to help assess effectiveness of dengue vaccine

Irvine Scientific announces launch of BalanCD MDCK cell culture medium

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

New drug combination proves effective in treating patients with HCV genotype 1

High cost of potent hepatitis drug presents challenges across the U.S.

Genetic evidence confirms role of group of virus-fighting genes in cancer development

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

New paper calls for increase in geographically targeted prevention, treatment for HIV-infected people

Findings pave way for potential therapy to combat H1N1 flu virus

New research provides new hope for liver transplant patients with recurring hepatitis C

Scientists discover protein potentially good target for influenza A virus

Too much of c-FLIPR protein can trigger autoimmune diseases

EU-funded project aims to find solution to combat hepatitis C epidemic in Egypt

Viral hepatitis linked to more deaths than HIV across EU countries

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Assembly Pharmaceuticals, BioCrossroads develop novel drugs that have potential to treat chronic HBV infection

Researchers discover how of EBV virus takes over human cells gene regulating machinery

Johns Hopkins student receives 2014 Excellence in Public Health Award

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

A new way of characterising biomolecules eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Newsletters you may be interested in